Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of immune system (general).

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

This was a multicenter, double-blind, placebo-controlled, intent-to-treat clinical trial.

What Was Measured

The subject headings attached to it are Antimicrobial Cationic Peptides, Cystic Fibrosis, Dietary Supplements, Forced Expiratory Volume, Immune System, Lung and Vitamin D.

The authors tagged it with the keywords cathelicidin, clinical trial, lung function, nutrition and pulmonary exacerbation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with immune system (general).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (The American journal of clinical nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Immune system (general) research.